Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome

Baldani,Dinka  Pavicic; Skrgatic,Lana; Cerne,Jasmina  Ziva; Oguic,Sasa  Kralik; Gersak,Blaz  Matija; Gersak,Ksenija

doi:10.3892/mmr.2014.3117

Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome

Authors:
- Dinka Pavicic Baldani
- Lana Skrgatic
- Jasmina Ziva Cerne
- Sasa Kralik Oguic
- Blaz Matija Gersak
- Ksenija Gersak
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, University of Zagreb Medical School, Division of Human Reproduction, University Medical Centre Zagreb, 10000 Zagreb, Croatia, Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Ljubljana SI‑1000, Slovenia, Clinical Institute of Laboratory Diagnostics, University Medical Centre Zagreb, 10000 Zagreb, Croatia, Faculty of Medicine, University of Ljubljana, Ljubljana SI‑1104, Slovenia
Published online on: December 19, 2014 https://doi.org/10.3892/mmr.2014.3117
Pages: 3941-3947

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to evaluate the influence of TAAAA repeat allele length on the levels of serum sex hormone binding globulin (SHBG) and cardiovascular risk factors in patients with polycystic ovary syndrome (PCOS). The study included 91 females with PCOS and 99 healthy controls. Phenotypic hyperandrogenism, body mass index and waist‑to‑hip ratio (WHR) were recorded. Hormonal profiles, fasting insulin and glucose levels, lipid profiles and C‑reactive protein (CRP) levels were measured. Genotyping of TAAAA repeat polymorphisms in the SHBG gene was performed. No significant difference was found in the frequency and distribution of TAAAA repeat alleles between PCOS patients and controls (P=0.739). In PCOS patients, SHBG levels were inversely correlated with serum C‑reactive protein (CRP) levels (R=−0.489, P<0.001). PCOS patients with long TAAAA repeat alleles had significantly lower serum SHBG and free testosterone levels, yet higher CRP levels than patients with short allele repeats. A multiple linear regression model using the number of TAAAA repeats, waist‑to‑hip ratio, a homeostatic model assessment of insulin resistance and age as independent predictors explained 44.8% of the variability in serum SHBG levels. In this model, TAAAA repeat polymorphism was found to be the only reliable predictor of serum SHBG levels (P<0.001). In conclusion, the TAAAA repeat polymorphism was shown to not be a major determinant of the PCOS status, although it influenced serum SHBG levels in females with PCOS. A strong independent association existed between serum SHBG and CRP levels. CRP is an established risk factor of cardiovascular disease and a marker of low‑grade inflammation, typical of atherogenesis. This may be one of the pathways by which low SHBG levels affect cardiovascular risk.

View Figures

View References

1	Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 19:41–47. 2004. View Article : Google Scholar
2	Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 81:19–25. 2004. View Article : Google Scholar
3	Carmina E, Chu MC, Longo RA, Rini GB and Lobo RA: Phenotypic variation in hyperandrogenic women influences the finding of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 90:2545–2549. 2005. View Article : Google Scholar : PubMed/NCBI
4	Boulman N, Levy Y, Leiba LR, Shachar S, et al: Increased C-reactive protein levels in polycystic ovary syndrome: a maker of cardiovascular disease. J Clin Endocrinol Metab. 89:2160–2165. 2004. View Article : Google Scholar : PubMed/NCBI
5	Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M and Tapanainen JS: Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:4649–4654. 2003. View Article : Google Scholar : PubMed/NCBI
6	Escobar-Morreale HF, Luque-Ramírez M and González F: Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 95:1048–1058. 2011. View Article : Google Scholar
7	Toulis KA, Goulis DG, Mintziori G, et al: Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 17:741–760. 2011. View Article : Google Scholar : PubMed/NCBI
8	Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH and van der Schouw YT: Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 40:189–207. 2011. View Article : Google Scholar
9	Speroff L, Glass RH and Kase NG: Anovulation and the polycystic ovary. Clinical Gynecologic Endocrinology and Infertility. Lippincott, Wiliams & Wilkins; Philadelphia, USA: pp. 487–521. 1999
10	Peter A, Kantartzis K, Machann J, et al: Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes. 59:3167–3173. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liao CH, Li HY, Yu HJ, et al: Low serum sex hormone-binding globulin: marker of inflammation? Clin Chim Acta. 413:803–807. 2012. View Article : Google Scholar : PubMed/NCBI
12	Bonnet F, Balau B, Malécot JM, et al: Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. Eur J Endocrinol. 161:81–85. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ding EL, Song Y, Manson JE, et al: Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 361:1152–1163. 2009. View Article : Google Scholar : PubMed/NCBI
14	Xita N and Tsatsoulis A: Genetic variants of sex hormone-binding globulin and their biological consequences. Mol Cell Endocrinol. 316:60–65. 2010. View Article : Google Scholar
15	Hogeveen KN, Talikka M and Hammond GL: Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem. 276:36383–36390. 2001. View Article : Google Scholar : PubMed/NCBI
16	Xita N, Tsatsoulis A, Chatzikyriakidou A and Georgiou I: Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab. 88:5976–5980. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ferk P, Teran N and Gersak K: The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod. 22:1031–1036. 2007. View Article : Google Scholar
18	Cousin P, Calemard-Michel L, Lejeune H, et al: Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab. 89:917–924. 2004. View Article : Google Scholar : PubMed/NCBI
19	Liu Q, Gu W, Cui B, et al: The association of TAAAAn repeat polymorphism in sex hormone-binding protein gene with polycystic ovary syndrome in Chinese population. Endocrine. 34:62–67. 2008. View Article : Google Scholar : PubMed/NCBI
20	Alevizaki M, Saltiki K, Xita N, et al: The importance of the (TAAAA)n alleles at the SHBG gene promoter for the severity of coronary artery disease in postmenopausal women. Menopause. 15:461–468. 2008. View Article : Google Scholar : PubMed/NCBI
21	Saltiki K, Stamatelopoulos K, Voidonikola P, et al: Association of the SHBG gene promoter polymorphism with early markers of atherosclerosis in apparently healthy women. Atherosclerosis. 219:205–210. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ferriman D and Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1440–1447. 1961. View Article : Google Scholar : PubMed/NCBI
23	Vermeulen A, Verdonck L and Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 84:3666–3672. 1999. View Article : Google Scholar : PubMed/NCBI
24	Friedewald WT, Levy RI and Fredericson DS: Estimation of the concentration of low density lipoprotein cholesterol without use of the ultracentrifuge. Clin Chem. 18:499–502. 1972.PubMed/NCBI
25	Tsatsoulis A: Developmental programming of polycystic ovary syndrome: role of prenatal androgen excess. Tsatsoulis A, Wyckoff J and Brown FM: Diabetes in Women: Pathophysiology and Therapy. Humana Press; New York, NY: pp. 83–103. 2009, View Article : Google Scholar
26	Baldani DP, Skrgatić L, Goldstajn MS, et al: Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol. 36:1413–1418. 2012.
27	González F, Rote NS, Minium J and Kirwan JP: Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab. 91:1508–1512. 2006. View Article : Google Scholar : PubMed/NCBI
28	González F, Rote NS, Minium J and Kirwan JP: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 91:336–340. 2006. View Article : Google Scholar
29	González F, Rote NS, Minium J and Kirwan JP: Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism. 58:954–962. 2009. View Article : Google Scholar : PubMed/NCBI
30	González F, Nair KS, Daniels JK, et al: Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab. 97:2836–2843. 2012. View Article : Google Scholar : PubMed/NCBI
31	González F: Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 77:300–305. 2012. View Article : Google Scholar :
32	Jain SK: Hyperglicemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J Biol Chem. 264:21340–21345. 1989.PubMed/NCBI
33	Aljada A, Thusu K, Amstrong D, Nicotera T and Dandona P: Increased carbonylation of proteins in diabetes. Diabetes. 44:113A1995.
34	Dandona P, Thusu K, Cook S, et al: Oxidative damage to DNA in diabetes mellitus. Lancet. 347:444–445. 1996. View Article : Google Scholar : PubMed/NCBI
35	Stephens JM, Butts MD and Pekala PH: Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocytedifferentiation by tumour necrosis factor-alpha. J Mol Endocrinol. 9:61–72. 1992. View Article : Google Scholar : PubMed/NCBI
36	Zwaka TP, Hombach V and Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 103:1194–1197. 2001. View Article : Google Scholar : PubMed/NCBI
37	Simó R, Barbosa-Desongles A, Sáez-Lopez C, et al: Molecular mechanism of TNFα-induced down-regulation of SHBG expression. Mol Endocrinol. 26:438–446. 2012. View Article : Google Scholar